Cargando…
Fluvoxamine for outpatients with COVID-19: where do we stand?
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Published by Elsevier Ltd.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8550914/ https://www.ncbi.nlm.nih.gov/pubmed/34717819 http://dx.doi.org/10.1016/S2214-109X(21)00501-5 |
| _version_ | 1784591056179822592 |
|---|---|
| author | Berwanger, Otavio |
| author_facet | Berwanger, Otavio |
| author_sort | Berwanger, Otavio |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8550914 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Published by Elsevier Ltd. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-85509142021-10-28 Fluvoxamine for outpatients with COVID-19: where do we stand? Berwanger, Otavio Lancet Glob Health Comment Published by Elsevier Ltd. 2022-01 2021-10-28 /pmc/articles/PMC8550914/ /pubmed/34717819 http://dx.doi.org/10.1016/S2214-109X(21)00501-5 Text en © 2022 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Comment Berwanger, Otavio Fluvoxamine for outpatients with COVID-19: where do we stand? |
| title | Fluvoxamine for outpatients with COVID-19: where do we stand? |
| title_full | Fluvoxamine for outpatients with COVID-19: where do we stand? |
| title_fullStr | Fluvoxamine for outpatients with COVID-19: where do we stand? |
| title_full_unstemmed | Fluvoxamine for outpatients with COVID-19: where do we stand? |
| title_short | Fluvoxamine for outpatients with COVID-19: where do we stand? |
| title_sort | fluvoxamine for outpatients with covid-19: where do we stand? |
| topic | Comment |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8550914/ https://www.ncbi.nlm.nih.gov/pubmed/34717819 http://dx.doi.org/10.1016/S2214-109X(21)00501-5 |
| work_keys_str_mv | AT berwangerotavio fluvoxamineforoutpatientswithcovid19wheredowestand |